Kobe University and Osaka University have found that the "neo-self-antibody" discovered in 2015 is frequently detected in women with recurrent miscarriage.
Recurrent miscarriage is a disease in which a baby can become pregnant but has repeated miscarriages and stillbirths and cannot give birth to a healthy baby.It is estimated that there are an estimated 140 million recurrent miscarriage patients in Japan, but the cause is unknown in more than half of them.
In 2015, Kobe University and Osaka University discovered a completely new autoantibody "neo-self-antibody" that causes "antiphospholipid antibody syndrome" that causes thrombosis, miscarriage, and preeclampsia.Since the symptoms of recurrent miscarriage are common to antiphospholipid antibody syndrome, it is said that a clinical study was conducted to clarify the relationship between recurrent miscarriage and neo-self-antibody.
Neo-self-antibodies were measured in 5 recurrent miscarriage women who visited outpatient clinics at five university hospitals nationwide, centered on Kobe University.As a result, 227 (52%) were positive for neo-self antibody, which was the highest frequency than other causes of recurrent miscarriage such as uterine morphology, hypothyroidism, and chromosomal abnormalities.In addition, a majority of 23 of the 227 females did not find the cause of recurrent pregnancy loss by conventional testing, but 121 (24%) of them were positive for neo-self-antibodies.In other words, it was suggested that neo-self-antibodies may be an important cause of recurrent miscarriage.
In the future, research on neo-self-antibodies is expected to elucidate the onset mechanism of recurrent miscarriage.In addition, it is said that this research group is also considering the development of drugs that suppress the production of neo-self-antibodies or inhibit their action, which may lead to the solution of the problem of declining birthrate and aging population. ..
Paper information:[Arthritis & Rheumatology] The β2-glycoprotein I / HLA-DR complex is the major autoantibody target in obstetric antiphospholipid syndrome